Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition

Zinger Key Points
  • Novartis is grappling with the looming loss of patent protection for key products, seeks new avenues for growth. 
  • Cytokinetics' cardiomyopathy drug is expected to generate sales of up to $3.6 billion by 2032.

Novartis AG NVS has decided to step back from pursuing the Cytokinetics Inc CYTK acquisition, dealing a blow to the potential deal with the promising heart-drug developer

The biotech company, currently running a sale process, leaves room for speculation on whether Novartis or another suitor might re-emerge or if the company will explore alternative options such as a capital raise.

Focused on developing muscle activators and inhibitors, Cytokinetics aims to provide potential treatments for individuals facing debilitating diseases affecting muscle performance. 

Also Read: Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch.

In November, Bloomberg reported that Cytokinetics was reportedly exploring potential takeover options as it has garnered interest from at least one major pharmaceutical company in recent months.

Citing Truist analysts, the Wall Street Journal reports the estimated Cytokinetics' cardiomyopathy drug sales of up to $3.6 billion by 2032. 

Novartis, grappling with the looming loss of patent protection for key products like heart drug Entresto, seeks new avenues for growth. 

While facing declining revenue in the coming years, the pharmaceutical giant's recent positive study results for drugs such as Kisqali and Pluvicto have boosted its stock. 

However, Chief Executive Vasant Narasimhan clarified on CNBC that the company's M&A strategy is centered on sub-$5 billion assets.

Price Action: CYTK shares are down 21.40% at $79.92 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapM&ANewsHealth CareMoversGeneralBriefsStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!